Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Depreciation & Amortization (CF) (2019 - 2025)

Harmony Biosciences Holdings' Depreciation & Amortization (CF) history spans 7 years, with the latest figure at $7000.0 for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) changed 0.0% year-over-year to $7000.0; the TTM value through Dec 2025 reached $20000.0, down 92.51%, while the annual FY2024 figure was $267000.0, 48.05% down from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $7000.0 at Harmony Biosciences Holdings, up from $6000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $164000.0 in Q4 2023 and bottomed at $6000.0 in Q4 2024.
  • The 5-year median for Depreciation & Amortization (CF) is $100000.0 (2021), against an average of $86105.3.
  • The largest YoY upside for Depreciation & Amortization (CF) was 58.25% in 2024 against a maximum downside of 96.34% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $117000.0 in 2021, then decreased by 8.55% to $107000.0 in 2022, then skyrocketed by 53.27% to $164000.0 in 2023, then plummeted by 96.34% to $6000.0 in 2024, then increased by 16.67% to $7000.0 in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Depreciation & Amortization (CF) are $7000.0 (Q3 2025), $6000.0 (Q2 2025), and $7000.0 (Q1 2025).